WEST POINT, Miss., Sept. 30, 2025 — Southern Ionics will invest in its Tuscaloosa, AL sulfur chemicals manufacturing facility to expand production capacity, make infrastructure improvements and add sodium metabisulfite production.

“We are pleased to make this investment and look forward to growing our business at Tuscaloosa. Our sulfur chemicals business serves industries that improve everyday life with uses in municipal water and wastewater treatment, pulp and paper production and chemicals manufacture. The addition of sodium metabisulfite is a natural extension of our sulfur chemicals business that strengthens our product offering for applications in the food, animal feed, chemicals and pharmaceuticals industries”, said Joe Stevens, President and Chief Operating Officer of Southern Ionics. “There is not enough sodium metabisulfite manufacturing capacity in North America to supply the market, forcing users reply upon imported product for their needs. Our Tuscaloosa facility is ideally suited to efficiently manufacture sodium metabisulfite to supply the North American market.”

Southern Ionics has operated the facility on Reichold Road in Tuscaloosa County since 1994. Construction will start in the fourth quarter of 2025.

About Southern Ionics

Founded in 1980 and family owned and operated, Southern Ionics manufactures sodium bisulfite, sodium thiosulfate and sodium sulfite solutions from three facilities located in Pasadena, TX, Tuscaloosa, AL and Williamsport, MD. The products are used in municipal and industrial water and wastewater treatment, pulp and paper production and chemicals manufacture.

Southern Ionics is a leading producer of aluminum, sulfur and ammonium chemicals. For more information, please visit our website at www.SouthernIonics.com.

SOURCE Southern Ionics

– DataJoint cierra una financiación inicial de 4,9 millones de dólares para revolucionar la gestión de datos y la IA en el ámbito académico y de las ciencias biológicas/farmacéuticas

BARCELONA, España y SALT LAKE CITY y AUSTIN, Texas, 30 de septiembre de 2025 — DataJoint, una plataforma líder de bases de datos computacionales e inteligencia artificial diseñada para optimizar la gestión de datos y acelerar la investigación en neurociencia, oncología y biología de sistemas, anunció hoy el cierre exitoso de su ronda de financiación inicial de 4,9 millones de dólares. La ronda fue codirigida por Nina Capital (con sede en Barcelona), Inoca Capital Partners (con sede en Salt Lake City) y Capital Factory (con sede en Austin), con la participación adicional de inversores existentes. La diversa base de inversores de DataJoint refleja el potencial comercial internacional de su plataforma. La compañía ya cuenta con clientes y socios en varios países.

La financiación permitirá a DataJoint escalar sus operaciones, optimizar su plataforma SaaS propia y expandir su alcance de mercado a empresas comerciales de ciencias de la vida y farmacéuticas en Estados Unidos y Europa. Con una propuesta de valor única que armoniza fuentes de datos multimodales y habilita flujos de trabajo complejos de IA/ML, DataJoint está preparada para aportar nuevas capacidades y abordar las ineficiencias en la gestión y reproducibilidad de datos en laboratorios de investigación de todo el mundo.

Además, DataJoint fue seleccionada recientemente para la 9ª edición de PharmStars, la aceleradora global líder en el sector farmacéutico para empresas emergentes de salud digital. Como parte de este programa, DataJoint colaborará con líderes farmacéuticos para explorar alianzas y oportunidades de innovación centradas en su innovadora plataforma.

La visión de un fundador

La historia de DataJoint comienza con el director de tecnología, Dimitri Yatsenko, cuya trayectoria en el mundo de la tecnología comenzó en Ucrania antes de cursar estudios de informática en Estados Unidos en la década de 1990. Al principio de su carrera, Dimitri trabajó en el desarrollo de bases de datos para seguridad pública y luego en una empresa emergente punto-com, donde aprendió la importancia de la ingeniería sólida y los modelos de datos rigurosos. Posteriormente, dirigió un equipo en GE Medical Systems, trabajando en imágenes quirúrgicas y navegación, donde la precisión y el control de calidad eran primordiales.

Posteriormente, Dimitri se unió a la emergente de neurociencia Ripple Neuro, lo que lo inspiró a cursar un doctorado en el Baylor College of Medicine. Durante sus estudios de posgrado, ayudó a fundar otra empresa de inteligencia artificial e imágenes médicas, nView Medical. Fue durante este periodo, en la intersección de la ingeniería y el descubrimiento científico, que Dimitri detectó una brecha crítica en la gestión de los datos de investigación y el desarrollo de los modelos de IA. Esta constatación lo impulsó a crear DataJoint, aportando la disciplina de la ingeniería y la innovación a los desafíos de la investigación científica moderna.

Transformando la gestión de datos en ciencias de la vida

La plataforma de DataJoint ya es utilizada por más de 100 laboratorios en Estados Unidos y Europa, incluyendo instituciones de primer nivel como Johns Hopkins, UCSF, Harvard y UCL. Al automatizar la estructuración, el procesamiento y el análisis de datos, la plataforma aborda desafíos críticos como la gestión fragmentada de datos, la baja reproducibilidad y la colaboración limitada en entornos de investigación. A medida que se expande a las compañías farmacéuticas, DataJoint continuará prestando servicios y colaborando con los Centros Médicos Académicos, en cuyo entorno se incubó originalmente la plataforma y ha demostrado su eficacia.

“Esta inversión nos permitirá ampliar nuestro alcance y seguir ofreciendo soluciones transformadoras a investigadores y organizaciones en ciencias de la vida”, afirmó Jim Olson, consejero delegado de DataJoint. “Con el apoyo de Nina Capital, Inoca Capital y Capital Factory, estamos bien posicionados para escalar nuestra plataforma y llevar el poder de la IA avanzada y la armonización de datos a un mercado más amplio”.

Apoyo de los inversores

Marta G. Zanchi, socia fundadora de Nina Capital, destacó las capacidades únicas de la plataforma:

“La base de datos computacional de DataJoint es una solución revolucionaria para la gestión de datos y la habilitación de IA en las ciencias de la vida. Su capacidad para optimizar los flujos de trabajo y mejorar la reproducibilidad la convierte en una herramienta crucial para impulsar el descubrimiento científico y la innovación. Nos complace apoyar al equipo en su misión de transformar la investigación y acelerar el progreso en la atención médica”.

Chris Sheffert, director general de Inoca Capital, destacó el potencial comercial de DataJoint:

“La plataforma de DataJoint se encuentra en una posición única para abordar los importantes desafíos a los que se enfrentan las empresas comerciales de ciencias de la vida y farmacéuticas. Desde la gestión de grandes cantidades de datos complejos hasta la obtención de información práctica mediante IA, las oportunidades de adopción en estas industrias son inmensas. Nos entusiasma asociarnos con DataJoint para que puedan escalar su tecnología transformadora”.

Acerca de DataJoint

Fundada para abordar las ineficiencias en los laboratorios de investigación académica y farmacéutica, DataJoint proporciona una infraestructura de base de datos unificada que armoniza las fuentes de datos multimodales en flujos de trabajo automatizados. La plataforma SaaS de la compañía se basa en un sistema de código abierto, con planes para lograr el cumplimiento de SOC2, HIPAA e ISO27001 para atender a una creciente base de clientes en el ámbito académico y la industria.

Acerca de Nina Capital

Nina Capital es una firma de capital de riesgo especializada que invierte exclusivamente en la intersección de la salud y la tecnología. Con sede en Barcelona, Nina Capital apoya a fundadores con necesidades específicas cuyas innovaciones transforman la atención médica a través de datos y capacidades informáticas. Desde su lanzamiento en 2019, Nina Capital ha invertido en 52 empresas en 18 países.

Acerca de Inoca Capital Partners

Inoca Capital Partners, con sede en Salt Lake City, es una firma de capital privado centrada en la colaboración con equipos directivos sólidos para impulsar el crecimiento y crear valor a largo plazo. Con experiencia en sectores como Datos + IA, Nube y Salud/TI, Inoca ayuda a las empresas a alcanzar objetivos ambiciosos mediante inversión estratégica y mentoría.

Acerca de Capital Factory

Capital Factory es el centro de atracción para emprendedores fuera de Silicon Valley, con sede en Austin, Texas. Con presencia en Austin, Dallas, Houston, San Antonio y Washington, D. C., conectan a empresas emergentes que transforman el mundo con inversores, clientes y talento, y han sido el inversor más activo de Texas desde 2010, según Pitchbook.

Acerca de PharmStars

PharmStars es la aceleradora de empresas emergentes de salud digital, centrada en la industria farmacéutica y basada en miembros. Gracias a nuestra experiencia en el sector farmacéutico, empresas emergentes, salud digital e innovación, comprendemos los desafíos a los que se enfrentan las empresas farmacéuticas y las empresas emergentes al buscar colaboración. Nuestro programa PharmaU^TM apoya a las empresas emergentes de salud digital y a nuestros miembros farmacéuticos para “cerrar la brecha entre la industria farmacéutica y las empresas emergentes, lo que se traduce en un mayor éxito y una adopción más rápida de soluciones “más allá de la molécula”. Más información en www.PharmStars.com.

Para consultas de medios:
DataJoint
Jim Olson, consejero delegado
[email protected]

Nina Capital
[email protected]

Inoca Capital Partners
[email protected]

Capital Factory
[email protected]

Logo – https://mma.prnewswire.com/media/2783095/DataJoint_Logo_Logo.jpg

BARCELONA, Spanien, und SALT LAKE CITY sowie AUSTIN, Texas, 30. September 2025 — DataJoint, eine führende computergestützte Datenbank- und KI-Plattform zur Rationalisierung der Datenverwaltung und Beschleunigung der Forschung in den Bereichen Neurowissenschaften, Onkologie sowie Systembiologie, gab heute den erfolgreichen Abschluss einer Finanzierungsrunde in Höhe von 4,9 Millionen US-Dollar bekannt. Die Runde wurde von Nina Capital mit Sitz in Barcelona, Inoca Capital Partners mit Sitz in Salt Lake City sowie Capital Factory mit Sitz in Austin angeführt, mit zusätzlicher Beteiligung von bestehenden Investoren. Die geografisch breit gefächerte Investorenbasis von DataJoint spiegelt das internationale kommerzielle Potenzial der Plattform wider. Das Unternehmen hat bereits Kunden und Partner in mehreren Ländern.

Die Finanzierung wird DataJoint in die Lage versetzen, seinen Betrieb zu skalieren, seine firmeneigene SaaS-Plattform zu verbessern sowie seine Marktreichweite auf kommerzielle Biowissenschafts- und Pharmaunternehmen in den Vereinigten Staaten sowie in Europa auszuweiten. Mit seinem einzigartigen Nutzenversprechen, multimodale Datenquellen zu harmonisieren und komplexe KI/ML-Workflows zu ermöglichen, ist DataJoint in der Lage, neue Möglichkeiten zu bieten und Ineffizienzen bei der Datenverwaltung und Reproduzierbarkeit in Forschungslabors weltweit zu beseitigen.

Darüber hinaus wurde DataJoint vor kurzem für die 9. Kohorte von PharmStars ausgewählt, dem führenden globalen Beschleuniger für Startups im Bereich der digitalen Gesundheit mit Schwerpunkt Pharma. Im Rahmen dieses Programms wird DataJoint mit führenden Pharmaunternehmen in Kontakt treten, um Partnerschaften und Innovationsmöglichkeiten rund um seine bahnbrechende Plattform auszuloten.

Die Vision eines Gründers

Die Geschichte von DataJoint beginnt mit dem technischen Leiter „CTO Dimitri Yatsenko“, dessen Weg in die Technologie in der Ukraine begann, bevor er in den 1990er Jahren ein Informatikstudium in den Vereinigten Staaten absolvierte. Zu Beginn seiner Karriere arbeitete Dimitri in der Datenbankentwicklung für die öffentliche Sicherheit und anschließend bei einem Dot-Com-Startup, wo er die Bedeutung von solider Technik sowie strengen Datenmodellen kennenlernte. Anschließend leitete er ein Team bei GE Medical Systems, das sich mit chirurgischer Bildgebung und Navigation befasste, wobei Präzision sowie Qualitätskontrolle von größter Bedeutung waren.

Später schloss sich Dimitri dem neurowissenschaftlichen Startup Ripple Neuro an, was ihn dazu inspirierte, am Baylor College of Medicine zu promovieren. Während seines Studiums half er bei der Gründung eines weiteren Unternehmens für KI und medizinische Bildgebung, nView Medical. In dieser Zeit erkannte Dimitri an der Schnittstelle zwischen Technik und wissenschaftlicher Forschung eine kritische Lücke in der Verwaltung von Forschungsdaten und der Entwicklung von KI-Modellen. Diese Erkenntnis veranlasste ihn, DataJoint zu gründen, um den Herausforderungen der modernen wissenschaftlichen Forschung mit technischer Disziplin und Innovation zu begegnen.

Umgestaltung des Datenmanagements in den Biowissenschaften

Die Plattform von DataJoint wird bereits von mehr als 100 Labors in den USA und Europa genutzt, darunter so renommierte Einrichtungen wie Johns Hopkins, UCSF, Harvard sowie UCL. Durch die Automatisierung der Datenstrukturierung, -verarbeitung und -analyse begegnet die Plattform kritischen Herausforderungen wie der fragmentierten Datenverwaltung, der schlechten Reproduzierbarkeit sowie der eingeschränkten Zusammenarbeit in Forschungsumgebungen. Während DataJoint auf Pharmaunternehmen expandiert, wird das Unternehmen weiterhin mit akademischen medizinischen Zentren zusammenarbeiten, in deren Umfeld die Plattform ursprünglich entwickelt wurde und ihre Effektivität bewiesen hat.

„Diese Investition wird uns ermöglichen, unsere Reichweite zu vergrößern und weiterhin transformative Lösungen für Forscher sowie Organisationen in den Biowissenschaften zu liefern”, sagte Jim Olson, Geschäftsführer von DataJoint. „Mit der Unterstützung von Nina Capital, Inoca Capital und Capital Factory sind wir gut positioniert, um unsere Plattform zu skalieren sowie die Leistungsfähigkeit von fortschrittlicher KI und Datenharmonisierung einem breiteren Markt zugänglich zu machen.”

Unterstützung für Investoren

Marta G. Zanchi, Gründungspartnerin von Nina Capital, hob die einzigartigen Fähigkeiten der Plattform hervor:
„Die rechnergestützte Datenbank von DataJoint ist eine bahnbrechende Lösung für Datenmanagement und KI-Einsatz in den Biowissenschaften. Ihre Fähigkeit, Arbeitsabläufe zu rationalisieren und die Reproduzierbarkeit zu verbessern, macht sie zu einem wichtigen Instrument, um wissenschaftliche Entdeckungen und Innovationen voranzutreiben. Wir freuen uns sehr, das Team bei seiner Aufgabe zu unterstützen, die Forschung zu verändern und den Fortschritt im Gesundheitswesen zu beschleunigen.”

Chris Sheffert, geschäftsführender Direktor bei Inoca Capital, hob das kommerzielle Potenzial von DataJoint hervor:
„Die Plattform von DataJoint ist einzigartig positioniert, um die großen Herausforderungen zu bewältigen, denen sich kommerzielle Life-Science- und Pharmaunternehmen gegenübersehen. Von der Verwaltung riesiger Mengen komplexer Daten bis hin zur Möglichkeit verwertbarer Erkenntnisse durch KI – die Möglichkeiten für eine Übernahme in diesen Branchen sind immens. Wir freuen uns, mit DataJoint zusammenzuarbeiten, während sie ihre transformative Technologie skalieren.”

Informationen zu DataJoint

DataJoint wurde gegründet, um Ineffizienzen in akademischen und pharmazeutischen Forschungslabors zu beseitigen, und bietet eine einheitliche Datenbankinfrastruktur, die multimodale Datenquellen in automatisierten Arbeitsabläufen harmonisiert. Die SaaS-Plattform des Unternehmens basiert auf einer Open-Source-Grundlage und soll SOC2-, HIPAA- sowie ISO27001-konform werden, um einen wachsenden Kundenstamm in Wissenschaft und Industrie zu bedienen.

Informationen zu Nina Capital

Nina Capital ist eine spezialisierte Risikokapitalgesellschaft, die ausschließlich an der Schnittstelle zwischen Gesundheitswesen und Technologie investiert. Nina Capital mit Sitz in Barcelona unterstützt bedarfsorientierte Gründer, deren Innovationen das Gesundheitswesen durch Daten- und Rechenkapazitäten verändern. Seit der Gründung im Jahr 2019 hat Nina Capital in 52 Unternehmen in 18 Ländern investiert.

Informationen zu Inoca Capital Partners

Inoca Capital Partners mit Sitz in Salt Lake City ist ein Private-Equity-Unternehmen, das sich auf die Zusammenarbeit mit starken Managementteams konzentriert, um das Wachstum voranzutreiben und langfristige Werte zu schaffen. Mit seiner Expertise in Branchen wie Daten + KI, Cloud und Gesundheitswesen/IT hilft Inoca Unternehmen, durch strategische Investitionen und Mentoring kühne Ziele zu erreichen.

Informationen zu Capital Factory

Capital Factory ist das Gravitationszentrum für Unternehmer außerhalb des Silicon Valley und hat seinen Hauptsitz in Austin, Texas. Mit Niederlassungen in Austin, Dallas, Houston, San Antonio und Washington, DC, bringen sie weltverändernde Startups mit Investoren, Kunden sowie Talenten zusammen und sind laut Pitchbook seit 2010 der aktivste Investor in Texas.

Informationen zu PharmStars

PharmStars ist der mitgliederbasierte, auf die Pharmaindustrie ausgerichtete Beschleuniger für Start-ups im Bereich der digitalen Gesundheit. Aufgrund unserer Expertise in den Bereichen Pharma, Start-ups, digitale Gesundheit und Innovation verstehen wir die Herausforderungen, denen sich Pharmaunternehmen sowie Start-ups bei der Zusammenarbeit gegenübersehen. Unser Programm PharmaU^TM unterstützt Start-ups im Bereich der digitalen Gesundheit und unsere Pharma-Mitglieder bei der „Überbrückung der Kluft zwischen Pharma und Start-up”, was zu größerem Erfolg und schnellerer Übernahme von Lösungen „jenseits des Moleküls” führt. Weitere Informationen finden Sie auf www.PharmStars.com.

Medienanfragen:
DataJoint
Jim Olson, Geschäftsführer
[email protected]

Nina Capital
[email protected]

Inoca Capital Partners
[email protected]

Capital Factory
[email protected]

Logo – https://mma.prnewswire.com/media/2783095/DataJoint_Logo_Logo.jpg

BARCELONA, Spain and SALT LAKE CITY and AUSTIN, Texas, Sept. 30, 2025 — DataJoint, a leading computational database and AI platform designed to streamline data management and accelerate research in neuroscience, oncology, and systems biology, today announced the successful closing of its $4.9M Seed funding round. The round was co-led by Barcelona-based Nina Capital, Salt Lake City-based Inoca Capital Partners, and Austin-based Capital Factory, with additional participation from existing investors. DataJoint’s geographically diverse investor base reflects the international commercial potential of its platform. The company already has customers and partners in multiple countries.

The funding will enable DataJoint to scale its operations, enhance its proprietary SaaS platform, and expand its market reach to commercial life sciences and pharmaceutical companies in the United States and in Europe. With a unique value proposition of harmonizing multimodal data sources and enabling complex AI/ML workflows, DataJoint is poised to bring new capabilities and address inefficiencies in data management and reproducibility in research labs worldwide.

Additionally, DataJoint was recently selected for the 9th cohort of PharmStars, the leading pharma-focused global accelerator for digital health startups. As part of this program, DataJoint will engage with pharma leaders to explore partnerships and innovation opportunities centered around its groundbreaking platform.

A Founder’s Vision

DataJoint’s story begins with CTO Dimitri Yatsenko, whose journey into tech started in Ukraine before pursuing computer science studies in the United States in the 1990s. Early in his career, Dimitri worked in database development for public safety and then at a dot-com startup, where he learned the importance of solid engineering and rigorous data models. He then led a team at GE Medical Systems, working on surgical imaging and navigation, where precision and quality control were paramount.

Later, Dimitri joined the neuroscience startup Ripple Neuro, inspiring him to pursue a PhD at Baylor College of Medicine. While in grad school, he helped launch another AI and medical imaging company, nView Medical. It was during this time, at the intersection of engineering and scientific discovery, that Dimitri recognized a critical gap in how research data was managed and AI models were developed. This realization drove him to create DataJoint, bringing engineering discipline and innovation to the challenges of modern scientific research.

Transforming Data Management in Life Sciences

DataJoint’s platform is already used by over 100 labs in the U.S. and Europe, including top-tier institutions such as Johns Hopkins, UCSF, Harvard, and UCL. By automating data structuring, processing, and analysis, the platform addresses critical challenges such as fragmented data management, poor reproducibility, and limited collaboration in research environments.  While expanding to pharma companies, DataJoint will continue to serve and collaborate with Academic Medical Centers, in whose environment the platform was originally incubated and has proven its effectiveness.

“This investment will allow us to expand our reach and continue delivering transformative solutions to researchers and organizations in life sciences,” said Jim Olson, CEO of DataJoint. “With the support of Nina Capital, Inoca Capital, and Capital Factory, we are well-positioned to scale our platform and bring the power of advanced AI and data harmonization to a broader market.”

Investor Support

Marta G. Zanchi, Founding Partner at Nina Capital, emphasized the platform’s unique capabilities:
“DataJoint’s computational database is a game-changing solution for data management and AI enablement in life sciences. Its ability to streamline workflows and improve reproducibility makes it a crucial tool for advancing scientific discovery and innovation. We are thrilled to support the team in their mission to transform research and accelerate progress in healthcare.”

Chris Sheffert, Managing Director at Inoca Capital, highlighted the commercial potential of DataJoint:
“DataJoint’s platform is uniquely positioned to address the significant challenges faced by commercial life science and pharmaceutical companies. From managing vast amounts of complex data to enabling actionable insights through AI, the opportunities for adoption in these industries are immense. We are excited to partner with DataJoint as they scale their transformative technology.”

About DataJoint

Founded to address inefficiencies in academic and pharmaceutical research labs, DataJoint provides a unified database infrastructure that harmonizes multimodal data sources into automated workflows. The company’s SaaS platform is built on an open-source foundation, with plans to achieve SOC2, HIPAA, and ISO27001 compliance to serve a growing customer base in academia and industry.

About Nina Capital

Nina Capital is a specialized venture capital firm investing exclusively at the intersection of healthcare and technology. Based in Barcelona, Nina Capital supports need-driven founders whose innovations transform healthcare through data and compute capabilities. Since its launch in 2019, Nina Capital has invested in 52 companies across 18 countries.

About Inoca Capital Partners

Inoca Capital Partners, based in Salt Lake City, is a private equity firm focused on partnering with strong management teams to drive growth and create long-term value. With expertise in industries such as Data + AI, Cloud, and Healthcare/IT, Inoca helps companies achieve bold goals through strategic investment and mentorship.

About Capital Factory

Capital Factory is the center of gravity for entrepreneurs outside of Silicon Valley, headquartered in Austin, Texas. With boots on the ground in Austin, Dallas, Houston, San Antonio, and Washington, DC, they connect world-changing startups with investors, customers, and talent—and have been Texas’ most active investor since 2010, according to Pitchbook.

About PharmStars

PharmStars is the member-based, pharma-focused accelerator for digital health startups. Because of our expertise across pharma, startups, digital health, and innovation, we understand the challenges that pharma and startups face when seeking to collaborate. Our PharmaU^TM program supports digital health startups and our pharma members in “bridging the pharma-startup gap,” leading to greater success and faster adoption of “beyond the molecule” solutions. More information at www.PharmStars.com.

For Media Inquiries:
DataJoint
Jim Olson, CEO
[email protected]

Nina Capital
[email protected]

Inoca Capital Partners
[email protected]

Capital Factory
[email protected]

SOURCE DataJoint

BARCELONE, Espagne et SALT LAKE CITY et AUSTIN, Texas, 30 septembre 2025 — DataJoint, une base de données computationnelle de premier plan et une plateforme d’IA conçue pour rationaliser la gestion des données et accélérer la recherche en neurosciences, en oncologie et en biologie des systèmes, annonce aujourd’hui la clôture de son cycle de fonds de démarrage de 4,9 millions USD. Ce tour de table a été mené conjointement par Nina Capital, basée à Barcelone, Inoca Capital Partners, basée à Salt Lake City, et Capital Factory, basée à Austin, avec la participation d’investisseurs existants. La diversité géographique des investisseurs de DataJoint reflète le potentiel commercial international de sa plateforme. L’entreprise compte déjà des clients et des partenaires dans de nombreux pays.

Ce financement permettra à DataJoint de développer ses activités, de renforcer sa plateforme SaaS propriétaire et d’étendre son marché aux entreprises pharmaceutiques et des sciences de la vie aux États-Unis et en Europe. Avec une proposition de valeur unique qui consiste à harmoniser les sources de données multimodales et à permettre des flux IA/ML complexes, DataJoint est prêt à apporter de nouvelles capacités et à remédier aux inefficacités en matière de gestion et de reproductibilité des données dans les laboratoires de recherche du monde entier.

En outre, DataJoint a récemment été sélectionné pour la 9e cohorte de PharmStars, le principal accélérateur mondial de startups dans le domaine de la santé numérique, axé sur l’industrie pharmaceutique. Dans le cadre de ce programme, DataJoint s’entretiendra avec des leaders de l’industrie pharmaceutique afin d’explorer des partenariats et des opportunités d’innovation autour de sa plateforme révolutionnaire.

La vision du fondateur

L’histoire de DataJoint commence avec Dimitri Yatsenko, CTO, dont le parcours dans la technologie a commencé en Ukraine avant de poursuivre des études d’informatique aux États-Unis dans les années 1990. Au début de sa carrière, Dimitri a travaillé dans le développement de bases de données pour la sécurité publique, puis dans une startup point-com, où il a appris l’importance d’une ingénierie solide et de modèles de données rigoureux. Il a ensuite dirigé une équipe chez GE Medical Systems, travaillant sur l’imagerie chirurgicale et la navigation, où la précision et le contrôle de la qualité étaient primordiaux.

Plus tard, Dimitri a rejoint la startup de neurosciences Ripple Neuro, ce qui l’a incité à poursuivre un doctorat au Baylor College of Medicine. Pendant ses études supérieures, il a participé au lancement d’une autre entreprise d’IA et d’imagerie médicale, nView Medical. C’est à cette époque, au carrefour de l’ingénierie et de la découverte scientifique, que Dimitri a constaté une lacune importante dans la gestion des données de recherche et le développement de modèles d’IA. Cette prise de conscience l’a poussé à créer DataJoint, en apportant la discipline et l’innovation de l’ingénierie aux défis de la recherche scientifique moderne.

Transformer la gestion des données dans les sciences de la vie

La plateforme de DataJoint est déjà utilisée par plus de 100 laboratoires aux États-Unis et en Europe, y compris des institutions de premier plan telles que Johns Hopkins, UCSF, Harvard et UCL. En automatisant la structuration, le traitement et l’analyse des données, la plateforme relève des défis critiques tels que la gestion fragmentée des données, la faible reproductibilité et la collaboration limitée dans les environnements de recherche.  Tout en s’étendant aux sociétés pharmaceutiques, DataJoint continuera à servir et à collaborer avec les CHU, un environnement dans lequel la plateforme a été incubée et a prouvé son efficacité.

« Cet investissement nous permettra d’étendre notre portée et de continuer à fournir des solutions transformatrices aux chercheurs et aux organisations dans le domaine des sciences de la vie », déclare Jim Olson, CEO de DataJoint. « Avec le soutien de Nina Capital, Inoca Capital et Capital Factory, nous avons toutes les cartes en main pour faire évoluer notre plateforme et apporter la puissance d’une IA de pointe et l’harmonisation des données à une clientèle plus large. »

Soutien des investisseurs

Marta G. Zanchi, associée fondatrice de Nina Capital, souligne les capacités uniques de la plateforme :
« La base de données computationnelle de DataJoint est une solution qui change la donne pour la gestion des données et l’activation de l’IA dans les sciences de la vie. Sa capacité à rationaliser les flux de travail et à renforcer la reproductibilité en fait un outil essentiel pour promouvoir la découverte et l’innovation scientifiques. Nous sommes ravis de soutenir l’équipe dans sa mission de transformation de la recherche et d’accélération des progrès dans le domaine des soins de santé ».

Chris Sheffert, directeur général d’Inoca Capital, souligne le potentiel commercial de DataJoint :
« La plateforme de DataJoint est idéalement positionnée pour relever les défis importants auxquels sont confrontées les entreprises pharmaceutiques et des sciences de la vie. De la gestion de vastes quantités de données complexes à l’obtention d’informations exploitables grâce à l’IA, les possibilités d’adoption dans ces secteurs sont immenses. Nous sommes ravis de travailler en partenariat avec DataJoint pour les accompagner dans le développement de cette technologie transformatrice ».

À propos de DataJoint

Fondé pour remédier aux inefficacités des laboratoires de recherche universitaires et pharmaceutiques, DataJoint fournit une infrastructure de base de données unifiée qui harmonise les sources de données multimodales dans des flux de travail automatisés. La plateforme SaaS de l’entreprise est construite sur une base open source, avec des projets pour obtenir la conformité SOC2, HIPAA et ISO27001 afin de servir une base de clients croissante dans les universités et l’industrie.

À propos de Nina Capital

Nina Capital est une société de capital-risque spécialisée qui investit exclusivement au carrefour des soins de santé et de la technologie. Basée à Barcelone, Nina Capital soutient les fondateurs dont les innovations transforment les soins de santé grâce aux données et aux capacités de calcul. Depuis son lancement en 2019, Nina Capital a investi dans 52 sociétés à travers 18 pays.

À propos d’Inoca Capital Partners

Inoca Capital Partners, basée à Salt Lake City, est une société de capital-investissement dont l’objectif est de s’associer à des équipes de direction expérimentées pour stimuler la croissance et créer de la valeur à long terme. Avec une expertise dans des secteurs tels que les données+IA, le cloud et les soins de santé/IT, Inoca aide les entreprises à atteindre des objectifs audacieux par le biais d’investissements stratégiques et de mentorat.

À propos de Capital Factory

Capital Factory, dont le siège se trouve à Austin, au Texas, est le centre de gravité des entrepreneurs en dehors de la Silicon Valley. Présente à Austin, Dallas, Houston, San Antonio et Washington, la société met en relation des startups d’envergure mondiale avec des investisseurs, des clients et des talents. Selon Pitchbook, la société est l’investisseur le plus actif du Texas depuis 2010.

À propos de PharmStars

PharmStars est l’accélérateur de startups de santé numérique basé sur ses membres et axé sur l’industrie pharmaceutique.Grâce à notre expertise dans les domaines de la pharmaceutique, des startups, de la santé numérique et de l’innovation, nous comprenons les défis auxquels sont confrontées les sociétés et les startups pharmaceutiques en recherche de collaboration. Notre programme PharmaU^TM soutient les startups de la santé numérique et nos membres de l’industrie pharmaceutique en « comblant le fossé entre l’industrie pharmaceutique et les startups », ce qui conduit à un plus grand succès et à une adoption plus rapide des solutions « au-delà de la molécule ». Plus d’informations sur www.PharmStars.com.

Relations avec les médias :
DataJoint
Jim Olson, CEO
[email protected]

Nina Capital
[email protected]

Inoca Capital Partners
[email protected]

Capital Factory
[email protected]

Logo – https://mma.prnewswire.com/media/2783095/DataJoint_Logo_Logo.jpg

Supernova launches Supernova Portal, an enterprise-grade vibe-coding platform that vastly accelerates the product development lifecycle, from ideation until final handoff to developers

Trusted by global brands like Air France, KLM, Kraft Heinz, Paramount, and Mozilla, Supernova will use Series A funding to accelerate product development and expand rapidly in the United States and around the world

PRAGUE and NEW YORK, Sept. 30, 2025 — Supernova, a platform uniting design, code and product to streamline digital teamwork, is announcing Supernova Portal, an enterprise-grade vibe-coding tool that empowers teams across all phases of product development, from ideation to delivery. The company also closed a $9.2 million Series A funding round to expand go-to-market efforts in the United States and across the globe. Portal is built on Supernova’s robust design system platform, trusted by hundreds of companies including Air France, KLM, Kraft Heinz, Paramount, and Mozilla to speed up product design and development.

“Product development is too slow and too complex, and it’s holding back innovation,” said Supernova CEO Jiri Trecak. “As an engineer and product leader, I’ve seen firsthand how silos and bottlenecks grind teams to a halt. We’ve spent nearly a decade building an enterprise-grade platform with some of the world’s most trusted companies – unifying design with code and supercharging it with AI – so teams can move from idea to production faster than ever, without abandoning the tools and processes they already rely on.”

Introducing Supernova Portal: AI-powered product development on one platform

For years, product teams have struggled with stretched-thin resources, endless back-and-forth between roles, documentation that drifts out of sync, and the constant challenge of selling ideas to stakeholders. Emerging trends like vibe-coding have offered partial relief, but none have integrated seamlessly into enterprise workflows – until now.

Supernova Portal brings the entire product lifecycle onto one platform and supercharges it with AI. Unlike tools like Lovable and v0 that focus only on rapid prototyping, Portal integrates with enterprise processes and maintains design system consistency from idea to code. With Portal, teams can:

• Transform ideas into complete product packages: Automatically generate PRDs, prototypes, and business cases, all synced to the codebase.
• Keep docs in sync: Update one document and Portal automatically reflects changes everywhere.
• Eliminate busywork with AI agents: Chat with AI agents that can handle manual tasks like updating requirements, syncing documentation, and resolving inconsistencies.
• Maintain standards automatically: Every output aligns with design systems, requirements, and brand guidelines.
• Plug into existing workflows: Portal connects with Figma, GitHub, VSCode, and more to seamlessly integrate with the tools teams already use.

Battle-tested by global brands, built for global scale

Supernova was founded in 2018 by CEO Jiri Trecak and COO Oskar Koristka, who previously built platforms and apps for the U.S. and Australian governments and other global enterprises. Frustrated by disconnected tools and fragmented data, they created Supernova to simplify design-to-code handoffs. Since then, the company has grown into a platform that unites the entire product development process. In 2019, Supernova became the first Czech startup accepted into Y Combinator.

Over the past seven years, Supernova has cultivated a loyal global customer base that includes some of the world’s most respected companies. Today, it powers hundreds of enterprise organizations – including Fortune 500 leaders – and has tripled both its user base and revenue in the past year. With its Series A, the company will establish a U.S. headquarters and significantly scale go-to-market operations in the U.S. and across the globe.

“We are proud to work together with Supernova, a company poised to define the future of product development,” said David Weng, CEO of Taiwania Capital. “Their unique knowledge architecture unifies design systems and code in an AI-powered platform that goes beyond prototyping, revolutionizing the entire product development lifecycle. Our investment is also a strategic partnership to accelerate Supernova’s expansion in Asia.”

“We invested in Supernova because it tackles one of the most painful and costly gaps in product development-design-to-code translation, especially in legacy systems,” said David Polach, general partner at J&T Ventures. “By automating routine design changes, Supernova frees up engineering teams to focus on high-value work, while scaling both team efficiency and client impact.”

“Supernova is doing for product development what Figma did for design: giving teams a single place to collaborate and move fast,” said Tomáš Obrtáč, general partner at KAYA VC. “The trust of such a significant number of international enterprises proves the strength of their vision. Central and Eastern Europe has a track record of producing founders who pair deep technical expertise with sharp commercial instincts, and Supernova is one of the most exciting examples of that.”

Supernova’s Series A is led by Taiwania Capital, known for helping companies expand globally, with participation from J&T Ventures, Reflex Capital, and existing backers Credo Ventures, EQT Ventures, Kaya, Wing VC, and Y Combinator.

About Supernova 

Supernova is an AI-powered product development platform that enables product teams to move from idea to production faster, smarter, and more efficiently. Supernova is trusted by hundreds of companies including Air France, Kraft Heinz, KLM, LaunchDarkly, Mews, Mozilla, Paramount, and Skyscanner, and backed by leading global investors including Credo Ventures, EQT Ventures, J&T Ventures, Kaya, Reflex Capital, Taiwania Capital, Wing VC, and Y Combinator.

SOURCE Supernova

Spark Capital Leads Series B Round as Eve Defines What It Means to Be an AI-Native Law Firm

SAN FRANCISCO, Sept. 30, 2025 — Eve, the AI platform transforming how plaintiff law firms deliver justice, today announced it has raised $103 million in Series B funding at over a $1 billion valuation. The round was led by Spark Capital, with participation from existing investors Andreessen Horowitz, Lightspeed Venture Partners, and Menlo Ventures.

Since its Series A round in January 2025, Eve has experienced unprecedented growth. The company has added over 350 new firms as customers in 8 months, bringing its total customer base to over 450 top firms, and making Eve one of the fastest-growing legal tech companies ever. The platform now processes more than 200,000 legal cases annually and has helped firms collectively recover over $3.5 billion in settlements and judgments.

Winning with AI

For plaintiff firms, winning means securing justice—justice for injured clients, for employees wronged by corporations, and for communities facing overwhelming odds. But plaintiff firms are strained by heavy workloads, growing case backlogs, and well-resourced defense teams.

“This is why we built Eve,” said Jay Madheswaran, CEO and co-founder of Eve. “Plaintiff firms fight for fairness against corporations with endless resources. This is no longer about keeping pace; it’s about seizing the upper hand. Firms must become AI-Native, reimagining their entire practice to outmaneuver the competition and deliver transformative wins for their clients. With this funding, we’ll arm them to do just that.”

AI Transformation for Plaintiff Firms

“To build the most advanced legal AI, we assembled an unparalleled team of AI engineers and legal experts,” said Madheswaran. “We gave them a singular mission: build a platform architected for the breakneck speed of modern AI.”

The result is Eve. Eve’s architecture is designed to be agile, allowing it to harness the latest breakthroughs from the AI industry, rigorously validate them for legal accuracy, and deploy them to clients through an easy-to-use interface and workflows faster than anyone else. Eve isn’t a static tool; it’s a continuous innovation platform.

This relentless technical advancement is backed by a dedicated client transformation team that ensures this power is tailored to a firm’s unique processes and values, making Eve a true extension of the firm. With Eve, the AI advantage doesn’t just happen once—it compounds over time, positioning firms to bring the best of their firm to their clients every time.

“We are standing on a massive shift in how law firms are run. From the bottom up, AI is going to be taking over and being a major part of your law firm,” said Mike Morse, founder of Mike Morse Law Firm. “For the last couple of years, AI was just for summarizing depositions and medical records, but it’s becoming so much more than that. And we’re weaving in AI, Eve, into everything we do.”

Customer Traction and Investment

Eve today serves over 450 of the most elite law firms in the nation, including Mike Morse Law Firm, The Law Offices of James Scott Farrin, Barrett & Farahany, Disparti Law Group, Frontier Law Center, Laurel Employment Law, and Hershey Law.

“Eve has transformed the way we work,” said Ryan Bliss, Partner & Head of Legal Technology at the Law Offices of James Scott Farrin. “We use it to streamline everything from medical summaries to settlement analysis memos, which frees up our attorneys to focus on strategy instead of paperwork.”

In the last year, firms have used Eve to achieve nuclear verdicts. Hershey Law won a $27 million settlement, and Geiger Legal Group won a $15 million case. Eve’s customers have been able to grow dramatically; some more than doubling their case capacity within a year of signing up for Eve.

“Eve represents exactly the kind of company we look for—one that’s fundamentally transforming how work gets done in a massive, traditional industry,” said James Kuklinski, General Partner at Spark Capital. “The legal industry has been ripe for this level of innovation, and Eve’s incredible traction serving hundreds of firms in less than two years since launching proves that plaintiff attorneys are ready to embrace AI-Native workflows. Jay and the team are building something much more important than efficiency tooling. They’re creating a new category of AI-Native law, raising the level of service that firms can offer to an increasing number of clients.”

About Eve

Eve is a leading Legal AI platform for Plaintiff Law Firms. Eve is designed to handle the heavy lifting of legal cases, from intake to resolution, by providing tools to enhance productivity and streamline workflows across the entire case lifecycle.

For more information, visit https://www.eve.legal/

SOURCE Eve

Founded by serial entrepreneur Iddo Gino, Datawizz is disrupting the broken LLM paradigm with Specialized Language Models that deliver >85% cost savings and faster, more accurate AI.

SAN FRANCISCO, Sept. 30, 2025 — Datawizz , the company pioneering Specialized Language Models (SLMs) as an alternative to large general-purpose LLMs, announces a $12.5M seed funding round led by Human Capital, with participation from BGV, 91VC, and others. The new capital will accelerate product development, expand the team, and fuel market entry across the U.S. and Europe.

Founded in 2025 by Iddo Gino, the entrepreneur who previously built RapidAPI into the world’s largest API marketplace, Datawizz addresses two critical challenges threatening the future of AI: unsustainable costs and inconsistent results.

“Companies spent $8.4B on API calls to LLMs in just the first half of 2025 – more than double the figure for all of 2024,” said Gino, Founder and CEO of Datawizz. “The pace of adoption is incredible. The challenge is that many applications have upside-down unit economics and deliver inconsistent results. Datawizz fixes this by replacing the massive generic models with smaller, Specialized Language Models that deliver faster, cheaper, and more accurate results.””Token costs for monolithic models break unit economics for many workloads” said Brian Blond, Investment Partner at Human Capital who will be joining Datawizz’s board. “Datawizz provides an elegant and essential solution that will become a core component of the AI stack, and we are thrilled to partner with them to build the next generation of AI”.

A New Paradigm: Specialized Language Models

While the AI industry has leaned heavily on increasingly large, general-purpose models, Datawizz is charting a different path. Its fully managed, end-to-end platform automatically profiles the organization’s AI requests, trains specialized expert models and automatically routes requests to them.

A company might have dozens of specialized models, each about 1,000 times smaller than a regular LLM, and trained to handle very specific requests. Datawizz routes every query to a specialized model best suited for the task, only defaulting to a general-purpose model when specialization isn’t available.

The results are transformative :

• >85% Reduction in AI Costs: Drastically cutting expenditures on API calls.
• 5-15x Improvement in Speed: Delivering faster, more responsive user experiences.
• Enhanced Precision: Achieving more accurate and predictable results, especially when fine-tuned with human feedback.

Unlike today’s reliance on Big Tech providers, Datawizz builds models that are completely owned by the customer, running on-premises, on-device, or in private clouds—ensuring no data is shared externally and eliminating dependency on external APIs.

By 2030, Datawizz predicts that ~70% of AI traffic will be served by sub-5B parameter Specialized Models, with more than 50% of that traffic managed through its platform.

Media Contact: [email protected] 

Datawizz was founded in 2025 by Iddo Gino, founder of RapidAPI. Based in San Francisco, the company is building the infrastructure for a sustainable AI future. Datawizz’s platform delivers efficient, economical, and reliable AI by replacing generic large models with Specialized Language Models that companies own and control. For more information, visit: https://datawizz.ai/

SOURCE Datawizz

Led by Canada’s first Microsoft Distinguished Enterprise Architect, Tato empowers system integrators to consistently deliver large-scale IT projects on time and on budget

MONTREAL, Sept. 30, 2025 — Tato, the AI-native project platform purpose-built for system integrators, today announced a $5 million Seed round led by Ridge Ventures, with participation from Myriad Venture Partners, Betaworks, RRE Ventures, and others. The funding will be used to scale the team as it continues to fix implementation problems that have crippled digital transformation for decades.

Since the 1990s , high-profile ERP (Enterprise Resource Planning) disasters have tormented companies like Nike, Hershey, PG&E, Waste Management, and Hewlett-Packard. Many Fortune 500 businesses spend up to 5% of annual revenue—hundreds of millions or more—to license, implement, and support ERP solutions. However, by 2027, more than 70% of recent ERP projects will fall short of desired business goals. Up to 25% will fail entirely.

Tato bridges the gap between agentic AI and seamless ERP implementation. Its AI-powered solution facilitates massive IT projects featuring dozens of workstreams, hundreds of stakeholders, constant changes, and stringent deadlines and budgets. Like a trusted colleague, Tato captures communications from calls, chats, and project management apps. This data then enters a real-time knowledge base that keeps teams organized and proactively flags issues.

Tato is primarily used by system integrators (SIs) to help manage ERP implementations. It simplifies communication, team onboarding, risk management, and other challenges faced by system integrators.

“I spent years watching ERP projects fail, companies lose millions, people lose their jobs,” said Justin Delisle, Tato co-founder and CEO. “AI can finally give projects the memory and foresight they’ve lacked.”

Tato’s key product features include:

• Capture and organize every interaction: Tato connects to meetings, chats, and project tools, automatically capturing activity and tagging it by participants, project references, and AI-driven analysis for accurate, secure organization.
• Enterprise security built in: With single-tenant architecture and SOC 2 compliance, Tato offers enterprise-grade security, flexible deployment, and context-aware access for every team member.
• Instant insights from project activity: Tato generates RAID logs, AI-assisted reports, and real-time summaries so teams stay informed and can track every decision.

“You couldn’t find a better team to transform ERP implementation,” said Akriti Dokania, Partner at Ridge Ventures. “Tato’s co-founders are domain experts and proven company- and product-builders. Justin is a globally recognized leader in the space. He speaks the language of system integrators stuck in ERP purgatory.”

Justin was Canada’s first Microsoft Distinguished Enterprise Architect and the youngest to receive the honor, one of 23 in the world at the time. His experience in enterprise IT consulting and project leadership, which includes the implementation of Microsoft Dynamics and other systems, spans more than a decade. Before founding Tato, Justin helped over 60 businesses implement ERPs.

Justin co-founded Tato with Head of Product Vlad Lokshin, a repeat founder who founded DarwinApps and Turtle, and Head of Go-to-Market Mathieu Chrétien, who helped scale Talent.com to more than $100 million in revenue.

Consulting firms like Gestisoft, Syntax, and Talan use Tato to keep IT projects on track. Tato decreased Gestisoft’s time spent on grunt work by 75% and reduced its team member onboarding time by 50%.

“We’re rolling out Tato across all of our projects,” said Frédérique Lacroix, Project Manager at Gestisoft. “We were skeptical at first, but the ability to instantly retrieve context from meetings we had weeks ago was a game-changer. What used to take days now takes minutes. Tato gives us back the time to focus on what matters, and in the end, the customer benefits most.”

Tato also works with enterprises such as Héroux Devtek, a landing gear manufacturer. Tato saved Héroux Devtek more than $500K by resolving scope disputes and many hours a week in efficiency.

“Working with Tato on our SAP ERP implementation was one of the best decisions we made,” said Michael Parke, IT Director at Héroux Devtek. “On a multi-site project spanning Canada, the US, the UK, and Spain, I couldn’t be everywhere at once. Tato automatically captured key details and decisions, even for meetings I missed, and acted as an unbiased third-party if any disputes arose. Tato’s visibility and recall are crucial for projects of this scale.”

About Tato

Founded in 2023, Tato is an AI-native project intelligence platform purpose-built to improve delivery of large-scale IT implementations, especially ERP projects. It captures all project communications, structures project data into a real-time knowledge base, and proactively surfaces risks, decisions, and updates across the project lifecycle. Learn more at www.tato.co

About Ridge Ventures

Founded in 2007, Ridge Ventures is a seed and early-stage venture capital firm investing in founders who are redefining how the world interacts with data and code. Ridge takes a fast, flexible, and founder-focused approach, and backs companies delivering advanced technologies, new distribution models, and incredible user experiences. Find out more at www.ridge.vc

Contacts
Mark Gavigan
(209) 298-7044
[email protected]

SOURCE Ridge Ventures